Table 1. Correlation between Pygo2 expression and clinicopathological features of human glioma tissues.
| Clinicopathological features | n | Pygo2 |
P valuea | |
|---|---|---|---|---|
| Over expression (%) | Nomal expression (%) | |||
| Age | ||||
| ≤50 years | 56 | 31 (55.36) | 25 (44.64) | 0.001* |
| >50 years | 153 | 121 (79.08) | 32 (20.92) | |
| Gender | ||||
| Male | 137 | 102 (74.45) | 35 (25.55) | 0.440 |
| Female | 72 | 50 (69.44) | 22 (30.56) | |
| Astrocytoma | ||||
| Anaplastic astrocytoma | 63 | 46 (73.02) | 17 (26.98) | 0.984 |
| Diffuse astrocytoma | 65 | 49 (75.38) | 16 (24.62) | |
| Yellow astrocytoma | 4 | 3 (75.00) | 1 (25.00) | |
| WHO phase | ||||
| I | 26 | 11 (42.31) | 15 (57.69) | 0.000* |
| II | 77 | 46 (59.74) | 31 (40.26) | |
| III | 59 | 48 (81.36) | 11 (18.64) | |
| IV | 47 | 44 (93.62) | 3 (6.38) | |
aStatistical significance was determined using Fisher’s exact test.
*Significant relation of clinicopathological features with glioma.